Literature DB >> 28264920

Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Teresa M Seccia1, Brasilina Caroccia1, Gail K Adler1, Giuseppe Maiolino1, Maurizio Cesari1, Gian Paolo Rossi2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28264920      PMCID： PMC5425097          DOI： 10.1161/HYPERTENSIONAHA.116.08956

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  69 in total

1.  Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation.

Authors:  A Goette; P Hoffmanns; W Enayati; U Meltendorf; J C Geller; H U Klein
Journal:  Am J Cardiol       Date:  2001-10-15       Impact factor: 2.778

2.  Vascular hypertrophy and remodeling in secondary hypertension.

Authors:  D Rizzoni; E Porteri; M Castellano; G Bettoni; M L Muiesan; P Muiesan; S M Giulini; E Agabiti-Rosei
Journal:  Hypertension       Date:  1996-11       Impact factor: 10.190

3.  Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes.

Authors:  Chin-Feng Tsai; Shun-Fa Yang; Hsiao-Ju Chu; Kwo-Chang Ueng
Journal:  Int J Cardiol       Date:  2013-10-08       Impact factor: 4.164

4.  Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat.

Authors:  Carina Lammers; Theresa Dartsch; Mathias C Brandt; Dennis Rottländer; Marcel Halbach; Gabriel Peinkofer; Simon Ockenpoehler; Marco Weiergraeber; Toni Schneider; Hannes Reuter; Jochen Müller-Ehmsen; Jürgen Hescheler; Uta C Hoppe; Carsten Zobel
Journal:  Cell Physiol Biochem       Date:  2012-05-11

5.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

6.  Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.

Authors:  Ulrik Dixen; Lasse Ravn; Christian Soeby-Rasmussen; Anders Wallin Paulsen; Jan Parner; Erik Frandsen; Gorm B Jensen
Journal:  Cardiology       Date:  2006-09-12       Impact factor: 1.869

7.  Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.

Authors:  G P Rossi; A Sacchetto; E Pavan; P Palatini; G R Graniero; C Canali; A C Pessina
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

8.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

Authors:  S Stewart; C L Hart; D J Hole; J J McMurray
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

9.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

10.  Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women.

Authors:  David Conen; Usha B Tedrow; Bruce A Koplan; Robert J Glynn; Julie E Buring; Christine M Albert
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690
View more
  17 in total

1.  Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial.

Authors:  Vibhu Parcha; Nirav Patel; Rajat Kalra; Joonseok Kim; Orlando M Gutiérrez; Garima Arora; Pankaj Arora
Journal:  Hypertension       Date:  2020-05-04       Impact factor: 10.190

Review 2.  Arterial Hypertension, Aldosterone, and Atrial Fibrillation.

Authors:  Teresa M Seccia; Brasilina Caroccia; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2019-11-18       Impact factor: 5.369

3.  Bidirectional Association Between Kidney Function and Atrial Fibrillation: A Population-Based Cohort Study.

Authors:  Anna C van der Burgh; Sven Geurts; M Arfan Ikram; Ewout J Hoorn; Maryam Kavousi; Layal Chaker
Journal:  J Am Heart Assoc       Date:  2022-05-17       Impact factor: 6.106

Review 4.  The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications.

Authors:  Teresa M Seccia; Brasilina Caroccia; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez; Gian Paolo Rossi
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 5.  Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management.

Authors:  Jakub Gumprecht; Magdalena Domek; Gregory Y H Lip; Alena Shantsila
Journal:  J Hum Hypertens       Date:  2019-11-05       Impact factor: 3.012

6.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

7.  Medical Versus Surgical Treatment of Primary Aldosteronism.

Authors:  David A Calhoun
Journal:  Hypertension       Date:  2018-02-26       Impact factor: 10.190

8.  Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

Review 9.  Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.

Authors:  Anand Vaidya; Robert M Carey
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

10.  New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies.

Authors:  Cheng-Hsuan Tsai; Ya-Li Chen; Chien-Ting Pan; Yen-Tin Lin; Po-Chin Lee; Yu-Wei Chiu; Che-Wei Liao; Zheng-Wei Chen; Chin-Chen Chang; Yi-Yao Chang; Chi-Sheng Hung; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.